Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gordana Vitaliano
Exqor Technologies, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
ExQor Technologies, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Vitaliano is the PI on the subcontract to McLean and has responsibility for the overall design, conduct, and reporting of the research conducted under the subcontract. Dr. Vitaliano and her spouse are co-founders of, and has an equity interest in, ExQor Technologies, Inc., a privately owned biotechnology company developing a range of non-invasive, CNS healthcare solutions. This research project is an SBIR subcontract from ExQor to further develop ExQor’s non-toxic, BDNF-nanoparticles (NPs), and to test the hypothesis that these NPs bypass the BBB intranasally, deliver BDNF to the brain, improve learning and memory, and reverse metabolic abnormalities and oxidative stress in the 3xTg mouse model of AD. The institution reviewed Dr. Vitaliano’s financial interest in ExQor in connection with this award and determined that it creates a conflict of interest with this research. The research could affect the value of ExQor’s technology and ExQor has an interest in new IP resulting from this research.
New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease
The development of a noninvasive, non-toxic nanotechnology for the prevention and treatment of AD will provide a significant therapeutic advance and fill a critical unmet medical need. The new drug would be able to enhance neuronal metabolism and plasticity, as well as restore brain functions quicker and better than existing treatment methods and with less side effects. This new nanotechnology would serve as a new drug delivery platform that could target relevant brain systems, and also may have utility as an imaging agent to enhance diagnosis and prognosis.
Filed on January 08, 2019.
Tell us what you know about Gordana Vitaliano's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Gordana Vitaliano filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Gordana Vitaliano | Exqor Technologies, Inc. | Conflict of Interest | ExQor Technologies, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.